|

Venetoclax Oral Tablet Clinical Trials

3 actively recruiting trials across 2 locations

Also known as: Venetoclax, venetoclax plus azacytidine

Pipeline

Phase 1: 1Phase 1/2: 1Phase 2/3: 1

Top Sponsors

  • The First Affiliated Hospital of Soochow University1
  • Montefiore Medical Center1
  • Aptose Biosciences Inc.1

Indications

  • Cancer3
  • Acute Myeloid Leukemia2
  • Myelodysplastic Syndrome With Excess Blasts-21
  • Relapsed Adult AML1
  • Chronic Myelomonocytic Leukemia1

Other1 trial

VA vs DA for Newly Diagnosed Hig-risk AML
Phase 2/3

Birmingham, Alabama1 trial

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia

The Kirklin Clinic of UAB Hospital

Phase 1/2

The Bronx, New York1 trial

Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

Montefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM)

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.